Skip to main content
Journal cover image

The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.

Publication ,  Journal Article
Morse, MA; Nair, SK; Boczkowski, D; Tyler, D; Hurwitz, HI; Proia, A; Clay, TM; Schlom, J; Gilboa, E; Lyerly, HK
Published in: Int J Gastrointest Cancer
2002

BACKGROUND: Resected pancreatic cancer has a high risk of recurrence and mortality despite the the use of chemoradiotherapy. Because pancreatic cancers express tumor antigens such as carcinoembryonic antigen (CEA), it may be possible to immunize patients to induce tumor antigen-specific immune responses. We hypothesize that high-frequency tumor antigen-specific immune responses will reduce recurrence and increase survival. Autologous dendritic cells (DCs) loaded with tumor antigens are particularly potent at inducing tumor antigen-specific immune responses. METHODS: Three patients with resected pancreatic adenocarcinoma following neoadjuvant chemoradiotherapy received autologous, monocyte-derived DCs loaded with the mRNA encoding CEA monthly for 6 mo. RESULTS: It was feasible to generate an adequate number of DC from these patients and to cryopreserve them for repeated use. The DC demonstrated the typical immature phenotype. The immunizations were well-tolerated without evidence of adverse events. All three developed injection site reactivity. All three are alive without evidence of disease at more than 2 1/2 yr from the original diagnosis. CONCLUSION: The postoperative period following neoadjuvant chemoradiotherapy and pancreaticoduodenectomy for pancreatic cancer is an ideal environment to test novel immune-based therapies. DC-based immunotherapy in this setting is safe and feasible and may lead to prolonged survival.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Gastrointest Cancer

DOI

ISSN

1537-3649

Publication Date

2002

Volume

32

Issue

1

Start / End Page

1 / 6

Location

United States

Related Subject Headings

  • Safety
  • Radiotherapy, Adjuvant
  • RNA, Messenger
  • Postoperative Period
  • Pancreaticoduodenectomy
  • Pancreatic Neoplasms
  • Neoadjuvant Therapy
  • Immunotherapy
  • Hypersensitivity, Delayed
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morse, M. A., Nair, S. K., Boczkowski, D., Tyler, D., Hurwitz, H. I., Proia, A., … Lyerly, H. K. (2002). The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer, 32(1), 1–6. https://doi.org/10.1385/IJGC:32:1:1
Morse, Michael A., Smita K. Nair, David Boczkowski, Douglas Tyler, Herbert I. Hurwitz, Alan Proia, Timothy M. Clay, Jeffrey Schlom, Eli Gilboa, and H Kim Lyerly. “The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.Int J Gastrointest Cancer 32, no. 1 (2002): 1–6. https://doi.org/10.1385/IJGC:32:1:1.
Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A, et al. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer. 2002;32(1):1–6.
Morse, Michael A., et al. “The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.Int J Gastrointest Cancer, vol. 32, no. 1, 2002, pp. 1–6. Pubmed, doi:10.1385/IJGC:32:1:1.
Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A, Clay TM, Schlom J, Gilboa E, Lyerly HK. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer. 2002;32(1):1–6.
Journal cover image

Published In

Int J Gastrointest Cancer

DOI

ISSN

1537-3649

Publication Date

2002

Volume

32

Issue

1

Start / End Page

1 / 6

Location

United States

Related Subject Headings

  • Safety
  • Radiotherapy, Adjuvant
  • RNA, Messenger
  • Postoperative Period
  • Pancreaticoduodenectomy
  • Pancreatic Neoplasms
  • Neoadjuvant Therapy
  • Immunotherapy
  • Hypersensitivity, Delayed
  • Humans